Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer.

Background: Tumor budding (TB) has emerged as a promising independent prognostic biomarker in colorectal cancer (CRC). The prognostic role of TB has been extensively studied and currently affects clinical decision making in patients with stage I and II CRC. However, existing prognostic studies on TB in stage III CRC have been confined to small retrospective cohort studies. Consequently, this study investigated the correlation among TB categories, clinicopathological features, and prognosis in stage III-IV CRC to further enhance the precision and individualization of treatment through refined prognostic risk stratification.
Aim: To analyze the relationship between TB categories and clinicopathological characteristics and assess their prognostic value in stage III-IV CRC to further refine the prognostic risk stratification of stage III-IV CRC.
Methods: The clinical data of 547 CRC patients were collected for this retrospective study. Infiltration at the front edge of the tumor buds was counted according to the 2016 International Tumor Budding Consensus Conference guidelines.
Results: Multivariate Cox proportional hazards regression analysis demonstrated that chemotherapy ( P = 0.004), clinical stage IV ( P < 0.001), ≥ 4 regional lymph node metastases ( P = 0.004), left-sided colonic cancer ( P = 0.040), and Bd 2-3 ( P = 0.002) were independent prognostic factors in patients with stage III-IV CRC. Moreover, the density of tumor infiltrating lymphocytes was higher in Bd 1 than in Bd 2-3, both in the tumor stroma and its invasive margin.
Conclusion: TB has an independent predictive prognostic value in patients with stage III-IV CRC. It is recommended to complete the TB report of stage III-IV CRC cases in the standardized pathological report to further refine risk stratification.
Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare.
(©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)